R
Ruben A. Mesa
Researcher at University of Texas Health Science Center at San Antonio
Publications - 720
Citations - 35662
Ruben A. Mesa is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Myelofibrosis & Ruxolitinib. The author has an hindex of 78, co-authored 632 publications receiving 30126 citations. Previous affiliations of Ruben A. Mesa include Wrocław Medical University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more
TL;DR: High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.
Journal ArticleDOI
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek,Ruben A. Mesa,Jason Gotlib,Richard S. Levy,Vikas Gupta,John F. DiPersio,John Catalano,Michael W. Deininger,Michael W. Deininger,Carole B. Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie H. Harvey,Murat O. Arcasoy,Elizabeth O. Hexner,Roger M. Lyons,Ronald Paquette,Azra Raza,Kris Vaddi,Susan Erickson-Viitanen,Iphigenia L. Koumenis,William Sun,Victor Sandor,Hagop M. Kantarjian +24 more
TL;DR: Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
Journal ArticleDOI
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer,Toni K. Choueiri,Dimpy P. Shah,Yu Shyr,Samuel M. Rubinstein,Donna R. Rivera,Sanjay Shete,Chih-Yuan Hsu,Aakash Desai,Gilberto Lopes,Petros Grivas,Petros Grivas,Corrie A. Painter,Solange Peters,Michael A. Thompson,Ziad Bakouny,Gerald Batist,Tanios Bekaii-Saab,Mehmet Asim Bilen,Nathaniel Bouganim,Mateo Bover Larroya,Daniel Castellano,Salvatore Del Prete,Deborah B. Doroshow,Pamela C Egan,Arielle Elkrief,Dimitrios Farmakiotis,Daniel Blake Flora,Matthew D. Galsky,Michael Glover,Elizabeth A. Griffiths,Anthony P. Gulati,Shilpa Gupta,Navid Hafez,Thorvardur R. Halfdanarson,Jessica Hawley,Emily Hsu,Anup Kasi,Ali Raza Khaki,Ali Raza Khaki,Christopher Lemmon,Colleen Lewis,Barbara Logan,Tyler Masters,Rana R. McKay,Ruben A. Mesa,Alicia K. Morgans,Mary F. Mulcahy,Orestis A. Panagiotou,Prakash Peddi,Nathan A. Pennell,Kerry L. Reynolds,Lane R. Rosen,Rachel P. Rosovsky,Mary Salazar,Andrew Schmidt,Sumit A. Shah,Justin Shaya,John A. Steinharter,Keith Stockerl-Goldstein,Suki Subbiah,Donald C. Vinh,Firas Wehbe,Lisa Weissmann,Julie Tsu Yu Wu,Elizabeth Marie Wulff-Burchfield,Zhuoer Xie,Albert C. Yeh,Albert C. Yeh,Peter Paul Yu,Alice Zhou,Leyre Zubiri,Sanjay Mishra,Gary H. Lyman,Gary H. Lyman,Brian I. Rini,Jeremy L. Warner,Maheen Z. Abidi,Jared D. Acoba,Neeraj Agarwal,Syed A. Ahmad,Archana Ajmera,Jessica K. Altman,Anne H. Angevine,Nilo Azad,Michael H. Bar,Aditya Bardia,Jill S. Barnholtz-Sloan,Briana Barrow,Babar Bashir,Rimma Belenkaya,Stephanie Berg,Eric H. Bernicker,Christine Bestvina,Rohit Bishnoi,Genevieve M. Boland,Mark Bonnen,Gabrielle Bouchard,Daniel W. Bowles,Fiona Busser,Angelo Cabal,Paolo Caimi,Theresa M. Carducci,Carla Casulo,James L. Chen,Jessica M. Clement,David D. Chism,Erin Cook,Catherine Curran,Ahmad Daher,Mark E. Dailey,Saurabh Dahiya,John F. Deeken,George D. Demetri,Sandy DiLullo,Narjust Duma,Rawad Elias,Bryan A. Faller,Leslie A. Fecher,Lawrence E. Feldman,Christopher R. Friese,Paul Fu,Julie Fu,Andy Futreal,Justin F. Gainor,Jorge A. Garcia,David Gill,Erin A. Gillaspie,Antonio Giordano,Grace Glace,Axel Grothey,Shuchi Gulati,Michael J. Gurley,Balazs Halmos,Roy S. Herbst,Dawn L. Hershman,Kent Hoskins,Rohit Jain,Salma K. Jabbour,Alokkumar Jha,Douglas B. Johnson,Monika Joshi,Kaitlin M. Kelleher,Jordan Kharofa,Hina Khan,Jeanna Knoble,Vadim S. Koshkin,Amit Kulkarni,Philip E. Lammers,John C. Leighton,Mark A. Lewis,X. Li,Ang Li,K. M.Steve Lo,Arturo Loaiza-Bonilla,Patricia LoRusso,Clarke A. Low,Maryam B. Lustberg,Daruka Mahadevan,Abdul Hai Mansoor,Michelle Marcum,Merry Jennifer Markham,Catherine Handy Marshall,Sandeep H. Mashru,Sara Matar,Christopher McNair,Shannon K. McWeeney,Janice M. Mehnert,Alvaro G. Menendez,Harry Menon,Marcus Messmer,Ryan Monahan,Sarah Mushtaq,Gayathri Nagaraj,Sarah Nagle,Jarushka Naidoo,John M. Nakayama,Vikram M. Narayan,Heather H. Nelson,Eneida R. Nemecek,Ryan Nguyen,Pier Vitale Nuzzo,Paul E. Oberstein,Adam J. Olszewski,Susie Owenby,Mary M. Pasquinelli,John Philip,Sabitha Prabhakaran,Matthew Puc,Amelie G. Ramirez,Joerg Rathmann,Sanjay G. Revankar,Young Soo Rho,Terence Duane Rhodes,Robert L. Rice,Gregory J. Riely,Jonathan Riess,Cameron Rink,Elizabeth Robilotti,Lori J. Rosenstein,Bertrand Routy,Marc A. Rovito,M. Wasif Saif,Amit Sanyal,Lidia Schapira,Candice Schwartz,Oscar K. Serrano,Mansi R. Shah,Chintan Shah,Grace Shaw,Ardaman Shergill,Geoffrey Shouse,Heloisa P. Soares,Carmen C. Solorzano,Pramod K. Srivastava,Karen Stauffer,Daniel G. Stover,Jamie Stratton,Catherine Stratton,Vivek Subbiah,Rulla M. Tamimi,Nizar M. Tannir,Umit Topaloglu,Eli Van Allen,Susan Van Loon,Karen Vega-Luna,Neeta K. Venepalli,Amit Verma,Praveen Vikas,Sarah Wall,Paul L. Weinstein,Matthias Weiss,Trisha Wise-Draper,William A. Wood,Wenxin Xu,Susan Yackzan,Rosemary Zacks,Tian Zhang,Andrea J. Zimmer,Jack West +239 more
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Journal ArticleDOI
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srdan Verstovsek,Hagop M. Kantarjian,Ruben A. Mesa,Animesh Pardanani,Jorge Cortes-Franco,Deborah A. Thomas,Zeev Estrov,Jordan S. Fridman,Edward C Bradley,Susan Erickson-Viitanen,Kris Vaddi,Richard S. Levy,Ayalew Tefferi +12 more
TL;DR: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.